{"id":979865,"date":"2026-07-08T16:14:08","date_gmt":"2026-07-08T20:14:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/"},"modified":"2026-07-08T16:14:08","modified_gmt":"2026-07-08T20:14:08","slug":"vaxcyte-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"Vaxcyte to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN CARLOS, Calif., July  08, 2026  (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Leerink Partners Therapeutics Forum, July 14-15, 2026: <\/strong>Meetings will take place on Wednesday, July 15.<\/p>\n<\/li>\n<li>\n          <strong>BTIG Virtual Biotechnology Conference, July 28-29, 2026: <\/strong>Meetings will take place on Tuesday, July 28.<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>About Vaxcyte\u00a0<\/strong><br \/>\n        <br \/>Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company\u2019s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company\u2019s PCV franchise.<\/p>\n<p>VAX-A1 is a prophylactic vaccine candidate designed to provide broad, strain-independent protection against disease caused by Group A Strep and is currently being evaluated in a Phase 1 clinical study in adults. Group A Strep remains a significant global cause of morbidity and mortality across both adult and pediatric populations and is a leading driver of antibiotic use, underscoring the substantial public health burden.<\/p>\n<p>Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF<sup>\u00ae<\/sup>, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company\u2019s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte\u2019s pipeline also includes VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0GKfpVCt_g4fDwR0j5kG-ryccV7fDtSWEDXn98TeI8x9yHAN2tciJy3OwpQQLlzf5tqWnEy9sQIEpDCGiKBukbqKk0YY-4KQVUkf27QrOy4a9WnNGleQtcD4unlIqckvTbw9fGs0J9RZYGlWgP9V2E6RefOkt2_enFZTNszgpmiTw13keTQqKCoWjaJVO3RJhUiiI3wVjorwa2yEsYes1yD2fnIimDOmdnEDm9HJEqZKZHdPGrIyxHtRNM_BLvc4btlOsyBP5zEkX28pgKOWd8k7bDaowvOOmMLCkYiOkxr1kkGV84MzjR06OezZTsnUWg_l50XSv1spgLd4PIRt2uT_OpFrOd-CVfjL2SSuQdnIAW8pce7b0X7rFqsvcgd4pFnsL8KmtQiR17MLP7tvwc929eK-3XrIZ8qtibki4mPrOft2iJn6SO8xTGEq8ArXwcztQ_JMTWMT7--VQqFm23WPd_3bk5IQctQDWPmsV4qBe1GJjQ-9H_mSX71OF2wRrj2po9YIyKEM6SKyqgw4cWRCv1uYqLuqO9VJAWxfVITAl46FCxIRbE-qNzsYJcuzFKalJ_sE4zjZkjW1ZpeUNxeAfJxAg3kaOHkcwnlvguDU-r8vQhuIXjfEkEzaCKrnWftmgSS0yQah0gluRxofnj24duFa5SFGoKzYIUk3iSPgHhPuS0zKD-WBIja5yQhHGn5VWMM7yCkM9ji_G1v1xVu5FSFvE-puwW4VQaoysmhNQr63BD07Ktjpb2MCSH6KfpyVibCMh1Tv1JgU8jVq_tBoP7YwrgWqd8Aso5qj_un8oh09IgefZGnUPaB0FnFFOU4II_PEPKd1nXmnwGDIPxScZxH-a1LvSgp7pxv8FLplplqQcZlMxwhjpkMlhqYSlsqDLd0_IxolXkX_2CL_QuQTXT5sTVXhzJT4WnTfo56NfsLgn3K3MT7yVWPAeqQaxhbQ_AFnMvJTKYfSrgdwxTx_GCiuW-zyPyohsewdmac_Jcy43cYAs9Ddha0dgO_POdcJwf2h02g38SC_LMnSCZ6t-w8sn6VapRWVk_BOA5szVwfWchsVvOe3IdKDEnY0dzSYuC5CUjiKkPC5aZlQ4d8J8i0tECrGXnmIKjKBSHBbLzC5aoPiJVB1wNNyFdziwfphy8m59CPKygjEGytxQwHtQ4cdbpq9hIBzr6x9AdlfjGqOrMKY2IiuJ1UA0b7-ZKYY3wpI0ABgNIkrtB6i4LTei14IUKWjVRYebV5cMW591aEMAU38SNIcGjw8ejECXjkYfMjrPIzZKxnsWpQHZvO27EkhlPhEXThGgC03kVBctqngxMABddlpZmNuOboe5BKd63ZOXCvSW1_owVc6bZJP_LUCWMVFWHV9GdPFwYijYU5I09JQlQGymA87g8jF9w0CVslPRfKMkS1Gs4U78LDeku1eKT-mjz9Lo_l-bbIYAqdhI13shb-6JsEmTQIFBWdbOScuPh_Ja_YnuzLOCPkYdEIQC5G5uEegLG5NbVzZZkCvl9qywRNbdfJNYRAgN4xrmucvTWLYopFXTSr-nF-bfD_RYNDNo3ZGTWrtW5QRzAj61vz_cFH4-xRYDYr__QkOwCfOQrezfgtDtGzAHrpb8HlqMCvCY3-fVQBCX6U-LtxqGVCHmqzknkKmSfqwjWMsRnsV9SWhbo8L3TEChXsGic9w6q8TLLvQ6piPDDydp6VaG7ZkHAL6yl1oimJoV4FLJBcIvzVzzH80xClhy3Gztdm1sGrcrCfaP0eBkitzicg8HlpYW_jtzNF9WuNS_nDNwoJvVUeMT7oMhC8UJAwD3zxWemnWbGQuLSDNLeT7lrT6mLXaxC0WR4jvPpfXQQ8eGIM23FVK16xBquSiAIalyFsavOKtvB6eeP9n8wMyc37z3JLyZmnDOB4plxXM7wZKIuTlEfqcAdu03MGv84yZ2qYUdOjVAV9x6C6fNhKjwlVfydU3xqRm6lKbiZ7sE4Ar0r3Z_Xoivy1U8G3erRYYeJoUWUKf66_jbxeQjBVQlDbCk2EZLiFdBKsMDewwAgYblxhCfclJeep6vYtCXX4MSGxweJeN8IY4RDN5Hkcep1_mqQ3ejx7F9eOGvIO4pOqMCB7HcezeK3fYMpmDvpk-ANeZck_Mz9GeczZFIxmY-WH27GdoifKbsVNx83USgsyYU5JiEisaXot7Nn8gK0FeavfWPqjSTXS5bFjhNwE_Ze97mZlKATgrDrmqlTDI\" rel=\"nofollow\" target=\"_blank\">www.vaxcyte.com<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <u>Contact:<\/u><br \/>\n        <\/strong><\/p>\n<p>Jeff Macdonald, Executive Director, Investor Relations<br \/>Vaxcyte, Inc.<br \/>917-371-0940<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-q7XGCuFKD5nuGlUnpDO1ayxbwQQacT1kapaHQMBoVs25PQ30dYSxs9YRnRUJQHgVnhmAbcwOFmE6ZNsoTIJtdu488CbgUHy1-VXgGTKhj2JRAE1r3efl7sCGFoX25Yv3JL9Fd7V1P9CaV1e7Tijvq0BxSPRYmmmhDD0tTRXwnGB368kyJU18m9KjthciurjXgytckvw91UZb97rSLBYUFny14XPFRdE82nJJ9XlF1vL7l5GXWK8Fq0NBEE_3l1pHxByfQiJXnpTcLzuS5CU4A==\" rel=\"nofollow\" target=\"_blank\">investors@vaxcyte.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1ODc2OCM3Njk1NjEzIzIxOTU4MjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDQ3MTUwNmEtYTg3OS00N2I2LWJlNDMtZDJmYjE3Nzg2ZmFhLTEyMDczNzctMjAyNi0wNy0wOC1lbg==\/tiny\/Vaxcyte-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences: Leerink Partners Therapeutics Forum, July 14-15, 2026: Meetings will take place on Wednesday, July 15. BTIG Virtual Biotechnology Conference, July 28-29, 2026: Meetings will take place on Tuesday, July 28. About Vaxcyte\u00a0 Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vaxcyte to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-979865","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaxcyte to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaxcyte to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences: Leerink Partners Therapeutics Forum, July 14-15, 2026: Meetings will take place on Wednesday, July 15. BTIG Virtual Biotechnology Conference, July 28-29, 2026: Meetings will take place on Tuesday, July 28. About Vaxcyte\u00a0 Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal &hellip; Continue reading &quot;Vaxcyte to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T20:14:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1ODc2OCM3Njk1NjEzIzIxOTU4MjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vaxcyte to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-07-08T20:14:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":366,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1ODc2OCM3Njk1NjEzIzIxOTU4MjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"Vaxcyte to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1ODc2OCM3Njk1NjEzIzIxOTU4MjQ=\",\"datePublished\":\"2026-07-08T20:14:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1ODc2OCM3Njk1NjEzIzIxOTU4MjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1ODc2OCM3Njk1NjEzIzIxOTU4MjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaxcyte to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaxcyte to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Vaxcyte to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences: Leerink Partners Therapeutics Forum, July 14-15, 2026: Meetings will take place on Wednesday, July 15. BTIG Virtual Biotechnology Conference, July 28-29, 2026: Meetings will take place on Tuesday, July 28. About Vaxcyte\u00a0 Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal &hellip; Continue reading \"Vaxcyte to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-08T20:14:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1ODc2OCM3Njk1NjEzIzIxOTU4MjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vaxcyte to Participate in Upcoming Investor Conferences","datePublished":"2026-07-08T20:14:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/"},"wordCount":366,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1ODc2OCM3Njk1NjEzIzIxOTU4MjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/","name":"Vaxcyte to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1ODc2OCM3Njk1NjEzIzIxOTU4MjQ=","datePublished":"2026-07-08T20:14:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1ODc2OCM3Njk1NjEzIzIxOTU4MjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1ODc2OCM3Njk1NjEzIzIxOTU4MjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vaxcyte to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/979865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=979865"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/979865\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=979865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=979865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=979865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}